456 related articles for article (PubMed ID: 35836249)
1. Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death.
Bao X; Xie L
J Exp Clin Cancer Res; 2022 Jul; 41(1):222. PubMed ID: 35836249
[TBL] [Abstract][Full Text] [Related]
2. Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor-Host Interaction and Therapeutic Perspectives.
de Andrade Mello P; Coutinho-Silva R; Savio LEB
Front Immunol; 2017; 8():1526. PubMed ID: 29184552
[TBL] [Abstract][Full Text] [Related]
3. Adenosine Generated by Regulatory T Cells Induces CD8
Shi L; Feng M; Du S; Wei X; Song H; Yixin X; Song J; Wenxian G
Biomed Res Int; 2019; 2019():4093214. PubMed ID: 31930120
[TBL] [Abstract][Full Text] [Related]
4. CD39/CD73/A2AR pathway and cancer immunotherapy.
Xia C; Yin S; To KKW; Fu L
Mol Cancer; 2023 Mar; 22(1):44. PubMed ID: 36859386
[TBL] [Abstract][Full Text] [Related]
5. Adenosine in cancer immunotherapy: Taking off on a new plane.
Zhang C; Wang K; Wang H
Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):189005. PubMed ID: 37913941
[TBL] [Abstract][Full Text] [Related]
6. The interplay between the DNA damage response and ectonucleotidases modulates tumor response to therapy.
Stagg J; Golden E; Wennerberg E; Demaria S
Sci Immunol; 2023 Jul; 8(85):eabq3015. PubMed ID: 37418547
[TBL] [Abstract][Full Text] [Related]
7. Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells.
Schuler PJ; Saze Z; Hong CS; Muller L; Gillespie DG; Cheng D; Harasymczuk M; Mandapathil M; Lang S; Jackson EK; Whiteside TL
Clin Exp Immunol; 2014 Aug; 177(2):531-43. PubMed ID: 24749746
[TBL] [Abstract][Full Text] [Related]
8. Targeting immunogenic cell death in cancer.
Ahmed A; Tait SWG
Mol Oncol; 2020 Dec; 14(12):2994-3006. PubMed ID: 33179413
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.
Bastid J; Regairaz A; Bonnefoy N; Déjou C; Giustiniani J; Laheurte C; Cochaud S; Laprevotte E; Funck-Brentano E; Hemon P; Gros L; Bec N; Larroque C; Alberici G; Bensussan A; Eliaou JF
Cancer Immunol Res; 2015 Mar; 3(3):254-65. PubMed ID: 25403716
[TBL] [Abstract][Full Text] [Related]
10. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
[TBL] [Abstract][Full Text] [Related]
11. Enhanced radiation-induced immunogenic cell death activates chimeric antigen receptor T cells by targeting CD39 against glioblastoma.
Sun T; Li Y; Yang Y; Liu B; Cao Y; Yang W
Cell Death Dis; 2022 Oct; 13(10):875. PubMed ID: 36245000
[TBL] [Abstract][Full Text] [Related]
12. The Immune Regulatory Role of Adenosine in the Tumor Microenvironment.
Xing J; Zhang J; Wang J
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834375
[TBL] [Abstract][Full Text] [Related]
13. Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.
Perrot I; Michaud HA; Giraudon-Paoli M; Augier S; Docquier A; Gros L; Courtois R; Déjou C; Jecko D; Becquart O; Rispaud-Blanc H; Gauthier L; Rossi B; Chanteux S; Gourdin N; Amigues B; Roussel A; Bensussan A; Eliaou JF; Bastid J; Romagné F; Morel Y; Narni-Mancinelli E; Vivier E; Paturel C; Bonnefoy N
Cell Rep; 2019 May; 27(8):2411-2425.e9. PubMed ID: 31116985
[TBL] [Abstract][Full Text] [Related]
14. Targeting adenosine and regulatory T cells in cancer immunotherapy.
Churov A; Zhulai G
Hum Immunol; 2021 Apr; 82(4):270-278. PubMed ID: 33610376
[TBL] [Abstract][Full Text] [Related]
15. CD39 - A bright target for cancer immunotherapy.
Guo S; Han F; Zhu W
Biomed Pharmacother; 2022 Jul; 151():113066. PubMed ID: 35550530
[TBL] [Abstract][Full Text] [Related]
16. Purinergic Signaling Within the Tumor Microenvironment.
Draganov D; Lee PP
Adv Exp Med Biol; 2021; 1270():73-87. PubMed ID: 33123994
[TBL] [Abstract][Full Text] [Related]
17. Purinergic signaling in liver disease.
Vaughn BP; Robson SC; Longhi MS
Dig Dis; 2014; 32(5):516-24. PubMed ID: 25034284
[TBL] [Abstract][Full Text] [Related]
18. The CD73/Ado System-A New Player in RT Induced Adverse Late Effects.
de Leve S; Wirsdörfer F; Jendrossek V
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31623231
[TBL] [Abstract][Full Text] [Related]
19. Adenosine signaling: Next checkpoint for gastric cancer immunotherapy?
Shi L; Yang L; Wu Z; Xu W; Song J; Guan W
Int Immunopharmacol; 2018 Oct; 63():58-65. PubMed ID: 30075429
[TBL] [Abstract][Full Text] [Related]
20. Conversion of extracellular ATP into adenosine: a master switch in renal health and disease.
Dwyer KM; Kishore BK; Robson SC
Nat Rev Nephrol; 2020 Sep; 16(9):509-524. PubMed ID: 32641760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
